Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Acadian Asset Management LLC

Acadian Asset Management LLC lessened its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 10.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,913,449 shares of the biotechnology company’s stock after selling 221,918 shares during the quarter. Acadian Asset Management LLC owned 2.69% of Aclaris Therapeutics worth $2,103,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Aclaris Therapeutics by 4.4% during the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock worth $6,113,000 after purchasing an additional 207,418 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Aclaris Therapeutics by 5,265.1% in the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 61,602 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 13,461 shares in the last quarter. Marquette Asset Management LLC purchased a new stake in shares of Aclaris Therapeutics during the first quarter worth about $104,000. Finally, Deuterium Capital Management LLC acquired a new position in shares of Aclaris Therapeutics in the first quarter worth about $99,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Analyst Ratings Changes

ACRS has been the topic of several analyst reports. StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 25th. HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a research note on Monday, August 19th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $23.00.

Aclaris Therapeutics Stock Up 0.9 %

NASDAQ:ACRS opened at $1.18 on Friday. The company has a market cap of $84.19 million, a PE ratio of -1.08 and a beta of 0.21. The business’s 50 day moving average is $1.24 and its two-hundred day moving average is $1.21. Aclaris Therapeutics, Inc. has a 52 week low of $0.59 and a 52 week high of $8.28.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.04. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. The firm had revenue of $2.77 million for the quarter, compared to analysts’ expectations of $1.74 million. As a group, sell-side analysts expect that Aclaris Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard acquired 173,730 shares of the stock in a transaction that occurred on Tuesday, July 30th. The stock was acquired at an average price of $1.30 per share, with a total value of $225,849.00. Following the transaction, the insider now directly owns 13,776,421 shares in the company, valued at $17,909,347.30. The acquisition was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders have acquired 1,080,502 shares of company stock worth $1,288,732. 6.40% of the stock is currently owned by insiders.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.